Latham & Watkins Advises the Underwriters in Allogene Therapeutics’ Public Offering

A capital markets team advised the underwriters in the transaction.

June 02, 2020

Allogene Therapeutics, Inc., has announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of US$47.00 per share. The gross proceeds from this offering are expected to be approximately US$550.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about June 4, 2020, subject to customary closing conditions. In addition, Allogene has granted the underwriters a 30-day option to purchase up to 1,755,319 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Latham & Watkins LLP represents the underwriters in the transaction with a capital markets team led by Bay Area partner Brian Cuneo and Orange County partner Shayne Kennedy, with Bay Area associates Phillip Stoup, Tess Bloom, and Taimi Jacobson. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards, with Bay Area counsel Betty Pang and Washington, D.C. associate Chad Jennings; on intellectual property matters by Bay Area partner Judith Hasko, with associate Gavin Liu; and on tax matters by Bay Area partner Grace Lee, with associate Jessica Chen.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.